Pin1 as a marker for prostate cancer
AssigneePintex Pharmaceuticals, Inc.
InventorsLere Bao, Da Gong Wang
Life of this patent
Estimating the term…
Abstract
This invention provides methods for diagnosing prostate cancer, methods for measuring the aggressiveness of prostate cancer, and methods for identifying prostate cancer likely to metastasize. The diagnostic and prognostic assays of this invention include methods involving the antibody-based detection of Pin 1 and the amplification of Pin 1 RNA. The diagnostic and prognostic assays of this invention may be used in combination with other methods of prostate cancer diagnosis including the PSA test, digital rectal exam, and Gleason prostate tumor grading system.
Claims40
A method for facilitating the diagnosis of prostate cancer in a subject, comprising:
- assessing the level of Pin1 in a biological sample from the subject, wherein an elevation in the level of Pin1 is indicative of prostate cancer;
- and evaluating a TDPCA on the subject such that the diagnosis of prostate cancer is facilitated.
A method for facilitating the diagnosis of prostate cancer in a subject, comprising:
- assessing the level of Pin1 in a biological sample from the subject, wherein an elevation in the level of Pin1 is indicative of prostate cancer, and wherein the subject was previously categorized by a TDPCA as being likely to have prostate cancer.
A method for measuring the aggressiveness of prostate cancer in a subject, comprising assessing the level of Pin1 in a biological sample from the subject, wherein an elevation in the level of Pin1 is indicative of the aggressiveness of the prostate cancer.
A method for identifying metastatic prostate cancer in a subject, comprising assessing the level of Pin1 in a biological sample from the subject, wherein an elevation in the level of Pin1 is indicative of metastatic prostate cancer.
A method of diagnosing prostate cancer in a subject, comprising:
- detecting a level of Pin1 nucleic acid in a biological sample;
- and
- comparing the level of Pin1 in the biological sample with a level of Pin1 in a control sample, wherein an elevation in the level of Pin1 in the biological sample compared to the control sample is indicative of prostate cancer.
A method of diagnosing prostate cancer metastasis in a subject, comprising the steps of:
- detecting a level of Pin1 nucleic acid in a biological sample;
- and
- comparing the level of Pin1 in the biological sample with a level of Pin1 in a control sample, wherein an elevation in the level of Pin1 in the biological sample compared to the control sample is indicative of prostate cancer metastasis.
A method for determining whether a subject having prostate cancer is likely to respond to treatment comprising a Pin1 inhibitor compound, the method comprising:
- assessing the level of Pin1 in a test sample from the subject;
- and
- comparing the level of Pin1 in the test sample to the level of Pin1 in normal tissue, whereby an increased level of Pin1 in the test sample is indicative that the subject is likely to respond to treatment comprising a Pin1 inhibitor compound.
A method of determining if a subject is at risk of developing metastatic prostate cancer comprising:
- assessing the level of Pin1 in a test sample from the subject;
- and
- determining if the level of Pin1 in the test sample is indicative of a cancer that will become metastatic.
A method of determining if a subject is at risk of developing PSA failure comprising:
- assessing the level of Pin1 in a test sample from the subject;
- and
- determining if the level of Pin1 in the test sample is indicative of developing PSA failure.
Dependencies are inferred from the claim text.